Clinical Trial Phases

#What phase labels mean

Phase terminology is commonly used in medicine development to describe the main purpose of a study. It is less useful for some other types of intervention. Labels provide a broad guide, but the study protocol is needed to understand the participants, comparisons, measurements and questions actually being investigated.

Development does not always follow a simple staircase. Studies may combine phases, overlap or return to earlier questions. Some programmes stop because of harms, insufficient benefit or other barriers. Reaching a later phase means further evaluation is taking place, not that success or eventual approval is assured.

#Early and middle phases

Phase 1 studies usually focus on initial safety, tolerability, dosing and how a medicine moves through or acts in the body. They often involve relatively few participants. Participants may be healthy volunteers or people with the condition, depending on the intervention and its potential risks.

Phase 2 studies generally explore whether there are signs of benefit in the intended population while continuing to assess safety and dose selection. Their size and design vary. A promising result can justify more research, but may be uncertain, depend on an indirect outcome or fail to hold up later.

#Later studies and continuing evaluation

Phase 3 studies usually aim to evaluate benefits and harms more definitively, often by comparing an intervention with an appropriate alternative in larger groups. Their findings can inform regulatory decisions. Nevertheless, even a large trial may miss uncommon harms or leave questions about longer-term effects unanswered.

Phase 4 generally refers to studies conducted after approval for use. These can investigate additional safety questions, effectiveness or particular populations. Not all monitoring after approval is a phase 4 trial, and research on a new use may require further earlier-phase or confirmatory studies.

#Common misunderstandings

A phase number is not a quality rating or a promise that a treatment works. Later phases usually address different questions from earlier ones, but important uncertainties can remain at every stage. A treatment studied in phase 3 may still prove ineffective or have harms that outweigh its benefits.

Early studies are not only about safety, and later studies are not only about effectiveness. Researchers may examine side effects, doses, treatment effects and how a medicine behaves in the body across several phases. Some trials combine phases, and not all types of treatment research use these labels.

Taking part in a trial does not guarantee access to the experimental treatment or better care outcomes. Depending on the design, participants may receive a comparison treatment or placebo. Approval also does not mean evaluation stops: further research and safety monitoring can reveal uncommon harms or effects that emerge over time.

#Questions worth asking a clinician

• What is this trial’s phase, and what does that tell us about its main research aims rather than its likelihood of success?
• If this is an early-phase trial, how will you assess safety, choose doses and look for initial treatment effects?
• What uncertainties about benefits and harms is this later-phase trial designed to address, and which are likely to remain?
• How do you decide whether findings justify further trials, and what could stop a treatment from moving to another phase?
• If the treatment is approved, what further research and safety monitoring are planned to identify longer-term benefits or harms?